Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer.
Irlam-Jones, Joely J Eustace, Amanda Denley, H Choudhury, Ananya Harris, A Hoskin, P West, Catharine M L
Irlam-Jones, Joely J
Eustace, Amanda
Denley, H
Choudhury, Ananya
Harris, A
Hoskin, P
West, Catharine M L
Citations
Altmetric:
Abstract
The addition of hypoxia modifiers carbogen and nicotinamide (CON) to radiotherapy (RT) improved overall survival (OS) in bladder cancer patients in the BCON phase III clinical trial. We investigate whether expression of hsa-miR-210 in BCON patient samples reflects hypoxia and predicts benefit from hypoxia modification.
Description
Date
2016-07-21
Publisher
Collections
Keywords
Type
Article
Citation
Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer. 2016: Br J Cancer